← Eichor
Study identifier: NCT06593106 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

Condition: Stage I Lung Cancer · Stage II Lung Cancer  ·  Sponsor: Vanderbilt-Ingram Cancer Center

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This clinical trial studies side effects and best treatment time of cryodevitalization in treating patients with early stage (stage I or stage II) lung cancer. Cryodevitalization is a type of cryosurgery that uses a flexible probe (cryoprobe) to kill tumor cells by freezing them. It is delivered at the time of standard diagnostic robotic bronchoscopy. Using cryodevitalization may be safe, tolerable and/or effective in treating patients with early stage lung cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Vanderbilt-Ingram Services for Timely Access  ·  800-811-8480  ·  cip@vumc.org

Always discuss trial participation with your own doctor first.

Locations (1)

Vanderbilt University/Ingram Cancer CenterNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06593106